Endometrioid carcinoma involving the uterus and ovary: distinguishing co-existence from metastasis in the molecular era

This publication has 20 references indexed in Scilit:

• Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
  The Lancet Oncology, 2025
• Co-existent endometrial and ovarian carcinoma: molecular and pathological features define low risk entity
  International Journal of Gynecological Cancer, 2025
• The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment
  International Journal of Gynecological Cancer, 2025
• Intraluminal tumor cells and prognostic accuracy of endometrial cancer stage criteria: A multi-institution study
  Gynecologic Oncology, 2023
• FIGO staging of endometrial cancer: 2023
  International Journal of Gynecology & Obstetrics, 2023
• Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death
  Laboratory Investigation, 2023
• Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
  The Lancet Oncology, 2019
• High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma
  Human Pathology, 2019
• Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial
  Gynecologic Oncology, 2018
• Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas
  JNCI: Journal of the National Cancer Institute, 2015